Tyrosine-protein kinase SYK
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count | Chain A； UniProt 360–635 | Fragment：UNP residues 360-635 Non-standard monomer：Yes (specific site not provided by mmCIF) | 6ZF 7-[6-(dimethylamino)pyridin-3-yl]-~{N}-[[(3~{S})-piperidin-3-yl]methyl]pyrido[3,4-b]pyrazin-5-amine × 1 GOL GLYCEROL × 5 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, SITTING DROP；pH 6.8；293 K；PEG1500, HEPES, TACSIMATE, GLYCEROL | Resolution 1.95 Å R-free 0.228 |
| 2 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count | Chain B； UniProt 360–635 | Fragment：UNP residues 360-635 Non-standard monomer：Yes (specific site not provided by mmCIF) | 6ZF 7-[6-(dimethylamino)pyridin-3-yl]-~{N}-[[(3~{S})-piperidin-3-yl]methyl]pyrido[3,4-b]pyrazin-5-amine × 1 GOL GLYCEROL × 2 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, SITTING DROP；pH 6.8；293 K；PEG1500, HEPES, TACSIMATE, GLYCEROL | Resolution 1.95 Å R-free 0.228 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 5LMB | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1A81 CRYSTAL STRUCTURE OF THE TANDEM SH2 DOMAIN OF THE SYK KINASE BOUND TO A DUALLY TYROSINE-PHOSPHORYLATED ITAM Deposited 1998-03-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain G
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
Chain I
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
Chain K
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；10% (W/V) PEG800, 10% (V/V) PEG 200, 0.1M TRIS HCL PH 8.5
|
Resolution 3.00 Å R-free 0.317 |
| 1A81 CRYSTAL STRUCTURE OF THE TANDEM SH2 DOMAIN OF THE SYK KINASE BOUND TO A DUALLY TYROSINE-PHOSPHORYLATED ITAM Deposited 1998-03-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
Chain C
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
Chain E
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；10% (W/V) PEG800, 10% (V/V) PEG 200, 0.1M TRIS HCL PH 8.5
|
Resolution 3.00 Å R-free 0.317 |
| 1A81 CRYSTAL STRUCTURE OF THE TANDEM SH2 DOMAIN OF THE SYK KINASE BOUND TO A DUALLY TYROSINE-PHOSPHORYLATED ITAM Deposited 1998-03-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；10% (W/V) PEG800, 10% (V/V) PEG 200, 0.1M TRIS HCL PH 8.5
|
Resolution 3.00 Å R-free 0.317 |
| 1A81 CRYSTAL STRUCTURE OF THE TANDEM SH2 DOMAIN OF THE SYK KINASE BOUND TO A DUALLY TYROSINE-PHOSPHORYLATED ITAM Deposited 1998-03-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain K
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；10% (W/V) PEG800, 10% (V/V) PEG 200, 0.1M TRIS HCL PH 8.5
|
Resolution 3.00 Å R-free 0.317 |
| 1A81 CRYSTAL STRUCTURE OF THE TANDEM SH2 DOMAIN OF THE SYK KINASE BOUND TO A DUALLY TYROSINE-PHOSPHORYLATED ITAM Deposited 1998-03-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain G
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；10% (W/V) PEG800, 10% (V/V) PEG 200, 0.1M TRIS HCL PH 8.5
|
Resolution 3.00 Å R-free 0.317 |
| 1A81 CRYSTAL STRUCTURE OF THE TANDEM SH2 DOMAIN OF THE SYK KINASE BOUND TO A DUALLY TYROSINE-PHOSPHORYLATED ITAM Deposited 1998-03-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；10% (W/V) PEG800, 10% (V/V) PEG 200, 0.1M TRIS HCL PH 8.5
|
Resolution 3.00 Å R-free 0.317 |
| 1A81 CRYSTAL STRUCTURE OF THE TANDEM SH2 DOMAIN OF THE SYK KINASE BOUND TO A DUALLY TYROSINE-PHOSPHORYLATED ITAM Deposited 1998-03-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 7 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain I
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；10% (W/V) PEG800, 10% (V/V) PEG 200, 0.1M TRIS HCL PH 8.5
|
Resolution 3.00 Å R-free 0.317 |
| 1A81 CRYSTAL STRUCTURE OF THE TANDEM SH2 DOMAIN OF THE SYK KINASE BOUND TO A DUALLY TYROSINE-PHOSPHORYLATED ITAM Deposited 1998-03-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 8 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain E
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；10% (W/V) PEG800, 10% (V/V) PEG 200, 0.1M TRIS HCL PH 8.5
|
Resolution 3.00 Å R-free 0.317 |
| 1CSY SYK TYROSINE KINASE C-TERMINAL SH2 DOMAIN COMPLEXED WITH A PHOSPHOPEPTIDEFROM THE GAMMA CHAIN OF THE HIGH AFFINITY IMMUNOGLOBIN G RECEPTOR, NMR Deposited 1995-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
163–265（103 aa）
Fragment：C-TERMINAL SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule | SOLUTION NMR mmCIF provides none of the parsed conditions | Resolution not provided |
| 1CSZ SYK TYROSINE KINASE C-TERMINAL SH2 DOMAIN COMPLEXED WITH A PHOSPHOPEPTIDEFROM THE GAMMA CHAIN OF THE HIGH AFFINITY IMMUNOGLOBIN G RECEPTOR, NMR Deposited 1995-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
163–265（103 aa）
Fragment：C-TERMINAL SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule | SOLUTION NMR mmCIF provides none of the parsed conditions | Resolution not provided |
| 1XBA Crystal structure of apo syk tyrosine kinase domain Deposited 2004-08-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
353–635（283 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；15% peg 3350, 100mM Tris HCl (pH 8.5)
|
Resolution 2.00 Å R-free 0.278 |
| 1XBB Crystal structure of the syk tyrosine kinase domain with Gleevec Deposited 2004-08-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
353–635（283 aa）
|
Not recorded | STI 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；15% peg 3350, 100mM Tris HCl (pH 8.5)
|
Resolution 1.57 Å R-free 0.221 |
| 1XBC Crystal structure of the syk tyrosine kinase domain with Staurosporin Deposited 2004-08-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
353–635（283 aa）
|
Not recorded | STU STAUROSPORINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；15% peg 3350, 100mM Tris HCl (pH 8.5)
|
Resolution 2.00 Å R-free 0.294 |
| 3BUW Crystal structure of c-Cbl-TKB domain complexed with its binding motif in Syk Deposited 2008-01-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
317–329（13 aa）
Fragment：UNP residues 317-329, pTyr-323 phosphopeptide
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.12M ammonium acetate, 18% PEG 3350, pH 6.5, vapor diffusion, hanging drop, temperature 298K
|
Resolution 1.45 Å R-free 0.238 |
| 3BUW Crystal structure of c-Cbl-TKB domain complexed with its binding motif in Syk Deposited 2008-01-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
317–329（13 aa）
Fragment：UNP residues 317-329, pTyr-323 phosphopeptide
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.12M ammonium acetate, 18% PEG 3350, pH 6.5, vapor diffusion, hanging drop, temperature 298K
|
Resolution 1.45 Å R-free 0.238 |
| 3BUW Crystal structure of c-Cbl-TKB domain complexed with its binding motif in Syk Deposited 2008-01-03 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
317–329（13 aa）
Fragment：UNP residues 317-329, pTyr-323 phosphopeptide
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.12M ammonium acetate, 18% PEG 3350, pH 6.5, vapor diffusion, hanging drop, temperature 298K
|
Resolution 1.45 Å R-free 0.238 |
| 3BUW Crystal structure of c-Cbl-TKB domain complexed with its binding motif in Syk Deposited 2008-01-03 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
317–329（13 aa）
Fragment：UNP residues 317-329, pTyr-323 phosphopeptide
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.12M ammonium acetate, 18% PEG 3350, pH 6.5, vapor diffusion, hanging drop, temperature 298K
|
Resolution 1.45 Å R-free 0.238 |
| 3EMG Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK) Deposited 2008-09-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
349–635（287 aa）
Fragment：Kinase domain: Residues 349-635
|
Not recorded | 685 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；10 mg/mL Protein, 15-20% PEG 8000, 100 mM Sodium nitrate, 100 mM HEPES pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 2.60 Å R-free 0.222 |
| 3FQE Crystal structure of spleen tyrosine kinase complexed with YM193306 Deposited 2009-01-07 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 365-635, Protein kinase domain
|
Not recorded | P5C 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；28% PEG 4000, 0.2M AMMONIUM SULFATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 2.50 Å R-free 0.253 |
| 3FQH Crystal structure of spleen tyrosine kinase complexed with a 2-substituted 7-azaindole Deposited 2009-01-07 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 365-635, Protein kinase domain
|
Not recorded | 057 N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；25% PEG 4000, 0.2M AMMONIUM SULFATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 2.26 Å R-free 0.259 |
| 3FQH Crystal structure of spleen tyrosine kinase complexed with a 2-substituted 7-azaindole Deposited 2009-01-07 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
356–635（280 aa）
Fragment：UNP residues 365-635, Protein kinase domain
|
Not recorded | 057 N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；25% PEG 4000, 0.2M AMMONIUM SULFATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 2.26 Å R-free 0.259 |
| 3FQS Crystal structure of spleen tyrosine kinase complexed with R406 Deposited 2009-01-07 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 365-635, Protein kinase domain
|
Not recorded | 585 6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；24% PEG 4000, 0.2M AMMONIUM SULFATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 2.10 Å R-free 0.253 |
| 3SRV Crystal structure of spleen tyrosine kinase (SYK) in complex with a diaminopyrimidine carboxamide inhibitor Deposited 2011-07-07 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
360–635（276 aa）
Fragment：KINASE DOMAIN (UNP Residues 360-635)
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | S19 2-{[(3R,4R)-3-aminotetrahydro-2H-pyran-4-yl]amino}-4-[(4-methylphenyl)amino]pyrimidine-5-carboxamide × 1 GOL GLYCEROL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；20% PEG3350, 0.2M Na-K-Phosphate, 0.1M Bis-Tris-Propane pH 6.5, 5mM DTT, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.95 Å R-free 0.241 |
| 3SRV Crystal structure of spleen tyrosine kinase (SYK) in complex with a diaminopyrimidine carboxamide inhibitor Deposited 2011-07-07 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
360–635（276 aa）
Fragment：KINASE DOMAIN (UNP Residues 360-635)
|
Not recorded | S19 2-{[(3R,4R)-3-aminotetrahydro-2H-pyran-4-yl]amino}-4-[(4-methylphenyl)amino]pyrimidine-5-carboxamide × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；20% PEG3350, 0.2M Na-K-Phosphate, 0.1M Bis-Tris-Propane pH 6.5, 5mM DTT, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.95 Å R-free 0.241 |
| 3TUB Crystal structure of SYK kinase domain with 1-(5-(6,7-dimethoxyquinolin-4-yloxy)pyridin-2-yl)-3-((1R,2S)-2-phenylcyclopropyl)urea Deposited 2011-09-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
Fragment：Spleen Tyrosine Kinase
|
Not recorded | FPU 1-{5-[(6,7-dimethoxyquinolin-4-yl)oxy]pyridin-2-yl}-3-[(1R,2S)-2-phenylcyclopropyl]urea × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；25% PEG 3350, 0.2M NaCl, 0.1M bis-Tris pH6.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.23 Å R-free 0.232 |
| 3TUC Crystal structure of SYK kinase domain with 1-benzyl-N-(5-(6,7-dimethoxyquinolin-4-yloxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide Deposited 2011-09-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
Fragment：Spleen Tyrosine Kinase
|
Not recorded | FPW 1-benzyl-N-{5-[(6,7-dimethoxyquinolin-4-yl)oxy]pyridin-2-yl}-2-oxo-1,2-dihydropyridine-3-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；25% PEG 1500, 0.1M bis-Tris pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.10 Å R-free 0.285 |
| 3TUD Crystal structure of SYK kinase domain with N-(4-methyl-3-(8-methyl-7-oxo-2-(phenylamino)-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)phenyl)-3-(trifluoromethyl)benzamide Deposited 2011-09-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
Fragment：Spleen Tyrosine Kinase
|
Not recorded | FPX N-{4-methyl-3-[8-methyl-7-oxo-2-(phenylamino)-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl]phenyl}-3-(trifluoromethyl)benzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.6；291 K；30% PEG MME 2000, 0.1M bis-Tris pH 6.6, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.33 Å R-free 0.263 |
| 3VF8 Crystal Structure of Spleen Tyrosine Kinase Syk Catalytic Domain with Pyrazolylbenzimidazole Inhibitor 416 Deposited 2012-01-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
Fragment：unp residues 343-635
|
Not recorded | 0JE 3-[5-(5-ethoxy-6-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 4.7；292 K；20% PEG3350, 0.1 M Na-citrate, 0.175 M K-phosphate, pH 4.7, VAPOR DIFFUSION, temperature 292K
|
Resolution 2.08 Å R-free 0.241 |
| 3VF9 Crystal Structure of Spleen Tyrosine Kinase Syk Catalytic Domain with Thienopyrazolylindole Inhibitor 027 Deposited 2012-01-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
Fragment：unp residues 343-635
|
Not recorded | 477 3-{2-[5-(difluoromethyl)-2H-thieno[3,2-c]pyrazol-3-yl]-1H-indol-6-yl}pentan-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 4.7；292 K；19% PEG3350, 0.1 M Na-citrate, 0.175 M K-phosphate, pH 4.7, VAPOR DIFFUSION, temperature 292K
|
Resolution 2.30 Å R-free 0.267 |
| 4DFL Crystal structure of spleen tyrosine kinase complexed with a sulfonamidopyrazine piperidine inhibitor Deposited 2012-01-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
363–635（273 aa）
|
Not recorded | 0K0 3-amino-6-{3-[(methylsulfonyl)amino]phenyl}-N-(piperidin-4-ylmethyl)pyrazine-2-carboxamide × 1 EDO 1,2-ETHANEDIOL × 1 SO4 SULFATE ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.98 Å R-free 0.243 |
| 4DFN Crystal structure of spleen tyrosine kinase complexed with an adamantylpyrazine inhibitor Deposited 2012-01-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
363–635（273 aa）
|
Not recorded | 0K1 3-amino-6-[3-(1-methyl-1H-pyrazol-4-yl)phenyl]-N-[(1R,2r,3S,5s,7s)-5-hydroxyadamantan-2-yl]pyrazine-2-carboxamide × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.48 Å R-free 0.273 |
| 4F4P SYK in COMPLEX WITH LIGAND LASW836 Deposited 2012-05-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
365–635（271 aa）
|
Not recorded | 0SB N-{6-[3-(piperazin-1-yl)phenyl]pyridin-2-yl}-4-(trifluoromethyl)pyridin-2-amine × 1 SO4 SULFATE ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.37 Å R-free 0.285 |
| 4FL1 Structural and Biophysical Characterization of the Syk Activation Switch Deposited 2012-06-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
|
Not recorded | ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0.1 M HEPES, 28% PEG 3350, 0.2 M ammonium sulfate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.79 Å R-free 0.225 |
| 4FL2 Structural and Biophysical Characterization of the Syk Activation Switch Deposited 2012-06-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–635（635 aa）
|
Not recorded | MG MAGNESIUM ION × 1 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；12% PEG 3350, 100 mM Hepes, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.19 Å R-free 0.228 |
| 4FL3 Structural and Biophysical Characterization of the Syk Activation Switch Deposited 2012-06-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–635（635 aa）
|
Mutation：Y348F, Y352F | ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；8% PEG 3350, 100 mM Hepes, 200 mM proline, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.208 |
| 4FYN Crystal structure of spleen tyrosine kinase complexed with 3-(8-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-phenylamino}-imidazo[1,2-a]pyrazin-5-yl)-phenol Deposited 2012-07-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：RESIDUES 356-635, PROTEIN KINASE DOMAIN
|
Not recorded | 0VE 3-[8-({4-[ethyl(2-hydroxyethyl)amino]phenyl}amino)imidazo[1,2-a]pyrazin-5-yl]phenol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；28% PEG 4000, 0.2M ammonium sulfate, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 2.32 Å R-free 0.269 |
| 4FYO Crystal structure of spleen tyrosine kinase complexed with N-{(S)-1-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-pyrrolidin-3-yl}-terephthalamic acid Deposited 2012-07-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：RESIDUES 356-635, PROTEIN KINASE DOMAIN
|
Not recorded | 0VF 4-{[(3S)-1-{7-[(3,4-dimethoxyphenyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}pyrrolidin-3-yl]carbamoyl}benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；28% PEG 4000, 0.2M ammonium sulfate, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 1.40 Å R-free 0.240 |
| 4FZ6 Crystal structure of spleen tyrosine kinase complexed with [6-((S)-2-Methyl-pyrrolidin-1-yl)-pyridin-2-yl]-(6-phenyl-imidazo[1,2-b]pyridazin-8-yl)-amine Deposited 2012-07-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：RESIDUES 356-635, PROTEIN KINASE DOMAIN
|
Not recorded | 0VG N-{6-[(2S)-2-methylpyrrolidin-1-yl]pyridin-2-yl}-6-phenylimidazo[1,2-b]pyridazin-8-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；28% PEG 4000, 0.2M ammonium sulfate, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 1.85 Å R-free 0.253 |
| 4FZ7 Crystal structure of spleen tyrosine kinase complexed with 6-((1R,2S)-2-Amino-cyclohexylamino)-4-(6-ethyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide Deposited 2012-07-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：RESIDUES 365-635, PROTEIN KINASE DOMAIN
|
Not recorded | 0VH 6-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(6-ethylpyridin-2-yl)amino]pyridazine-3-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；28% PEG 4000, 0.2M ammonium sulfate, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 1.75 Å R-free 0.250 |
| 4GFG Crystal structure of spleen tyrosine kinase complexed with r9021 Deposited 2012-08-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：Kinase domain
|
Not recorded | 0XF 6-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(5,6-dimethylpyridin-2-yl)amino]pyridazine-3-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；278 K；12% PEG 3350, 0.1M sodium malonate, pH 4.0, VAPOR DIFFUSION, SITTING DROP, temperature 278K
|
Resolution 2.35 Å R-free 0.246 |
| 4I0R Crystal structure of spleen tyrosine kinase complexed with 2-(3,4,5-Trimethoxy-phenyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide Deposited 2012-11-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain (UNP residues 356-635)
|
Not recorded | 1B4 N-(propan-2-yl)-2-(3,4,5-trimethoxyphenyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；28% PEG4000, 0.2 M ammonium sulfate, 0.1 M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 2.10 Å R-free 0.272 |
| 4I0S Crystal structure of spleen tyrosine kinase complexed with 2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide Deposited 2012-11-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain (UNP residues 356-635)
|
Not recorded | 1B5 2-(6-chloro-1-methyl-1H-indazol-3-yl)-N-(propan-2-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；28% PEG4000, 0.2 M ammonium sulfate, 0.1 M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 1.98 Å R-free 0.236 |
| 4I0T Crystal structure of spleen tyrosine kinase complexed with 2-(5,6,7,8-Tetrahydro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid tert-butylamide Deposited 2012-11-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain (UNP residues 356-635)
|
Not recorded | 1B6 N-tert-butyl-2-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；28% PEG4000, 0.2 M ammonium sulfate, 0.1 M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 1.70 Å R-free 0.268 |
| 4PUZ Crystal structure of spleen tyrosine kinase (Syk) in complex with GS-9973 Deposited 2014-03-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
353–635（283 aa）
Fragment：Syk kinase domain, UNP residues 356-635
|
Not recorded | CG9 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；15% PEG 3350, 100mM Tris pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.08 Å R-free 0.261 |
| 4PUZ Crystal structure of spleen tyrosine kinase (Syk) in complex with GS-9973 Deposited 2014-03-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
353–635（283 aa）
Fragment：Syk kinase domain, UNP residues 356-635
|
Not recorded | CG9 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；15% PEG 3350, 100mM Tris pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.08 Å R-free 0.261 |
| 4PV0 Crystal structure of spleen tyrosine kinase (Syk) in complex with an imidazopyrazine inhibitor Deposited 2014-03-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
363–635（273 aa）
Fragment：Syk kinase domain, UNP residues 363-635
|
Not recorded | CG4 4-[(3-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}benzoyl)amino]benzoic acid × 1 CL CHLORIDE ION × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.00 Å R-free 0.282 |
| 4PX6 SYK catalytic domain in complex with a potent pyridopyrimidinone inhibitor Deposited 2014-03-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：Catalytic Domain
|
Mutation：K467T | 2X6 7-{[(1R,2S)-2-aminocyclohexyl]amino}-5-(1H-indol-7-ylamino)pyrido[4,3-d]pyrimidin-4(3H)-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.2；293 K；20% PEG3350, 0.2M ammonium fluoride, pH 6.2, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.60 Å R-free 0.202 |
| 4RSS Crystal structure of tyrosine-protein kinase SYK with an inhibitor Deposited 2014-11-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP RESIDUES 356-635
|
Not recorded | 4MG 1-[(3-methyl-1-{2-[(1,2,3-trimethyl-1H-indol-5-yl)amino]pyrimidin-4-yl}-1H-pyrazol-4-yl)methyl]azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10-20% (v/v) PEG 3350, 100mM Tris-HCl (pH 8.5)
, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.83 Å R-free 0.249 |
| 4RX7 SYK Catalytic Domain Complexed with a Potent Triazine Inhibitor Deposited 2014-12-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：Protein kinase domain residues 356-635
|
Not recorded | FMT FORMIC ACID × 1 GOL GLYCEROL × 1 3YV 3-{[(1R,2S)-2-aminocyclohexyl]amino}-5-{[3-(2H-1,2,3-triazol-2-yl)phenyl]amino}-1,2,4-triazine-6-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6；293 K；20% PEG 3350, 0.2M ammonium formate, pH 6.0, vapor diffusion, temperature 293K
|
Resolution 1.80 Å R-free 0.203 |
| 4RX8 SYK Catalytic Domain Complexed with a Potent Triazine Inhibitor2 Deposited 2014-12-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：Protein kinase domain residues 356-635
|
Not recorded | GOL GLYCEROL × 2 3YX 3-{[(1R,2S)-2-aminocyclohexyl]amino}-5-(1H-indol-7-ylamino)-1,2,4-triazine-6-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.3；293 K；20% PEG 3350, 0.2M potassium formate, pH 7.3, vapor diffusion, temperature 293K
|
Resolution 1.59 Å R-free 0.207 |
| 4RX9 SYK Catalytic Domain Complexed with a Potent Pyrimidine Inhibitor Deposited 2014-12-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
|
Not recorded | GOL GLYCEROL × 1 3YT 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-{[3-(2H-1,2,3-triazol-2-yl)phenyl]amino}pyrimidine-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6；293 K；20% PEG 3350, 0.2M ammonium formate, pH 6.0, vapor diffusion, temperature 293K
|
Resolution 1.75 Å R-free 0.197 |
| 4WNM SYK catalytic domain in complex with a potent triazolopyridine inhibitor Deposited 2014-10-13 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | 3RT N~3~-(tetrahydro-2H-pyran-4-yl)-N~6~-[5-(tetrahydro-2H-pyran-4-ylmethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-1H-indazole-3,6-diamine × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；278 K；100 mM MES pH 5.3, 150 mM Ammonium sulfate, and 22% PEG 3350
|
Resolution 2.50 Å R-free 0.260 |
| 4XG2 Crystal structure of ligand-free Syk Deposited 2014-12-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.21 Å R-free 0.227 |
| 4XG3 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X3G 4-{[5-fluoro-4-(3-{[(3R)-3-hydroxypyrrolidin-1-yl]methyl}-4-methyl-1H-pyrrol-1-yl)pyrimidin-2-yl]amino}-2,6-dimethylphenyl methanesulfonate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20% (v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.30 Å R-free 0.226 |
| 4XG3 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X3G 4-{[5-fluoro-4-(3-{[(3R)-3-hydroxypyrrolidin-1-yl]methyl}-4-methyl-1H-pyrrol-1-yl)pyrimidin-2-yl]amino}-2,6-dimethylphenyl methanesulfonate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20% (v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.30 Å R-free 0.226 |
| 4XG4 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X4G (3R)-1-{[1-(5-fluoro-2-{[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]amino}pyrimidin-4-yl)-4-methyl-1H-pyrrol-3-yl]methyl}pyrrolidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.30 Å R-free 0.228 |
| 4XG6 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X6G 1-[(1-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-3-methyl-1H-pyrazol-4-yl)methyl]azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.40 Å R-free 0.230 |
| 4XG7 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X7G 1-[(3-methyl-1-{2-[(1-methyl-1H-indazol-5-yl)amino]pyrimidin-4-yl}-1H-pyrazol-4-yl)methyl]azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 1.76 Å R-free 0.242 |
| 4XG8 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X8G 1-[(1-{2-[(3-chloro-1-methyl-1H-indazol-5-yl)amino]pyrimidin-4-yl}-3-methyl-1H-pyrazol-4-yl)methyl]azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.40 Å R-free 0.275 |
| 4XG8 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X8G 1-[(1-{2-[(3-chloro-1-methyl-1H-indazol-5-yl)amino]pyrimidin-4-yl}-3-methyl-1H-pyrazol-4-yl)methyl]azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.40 Å R-free 0.275 |
| 4XG9 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X9G 1-[(1-{2-[(3-chloro-1,2-dimethyl-1H-indol-5-yl)amino]pyrimidin-4-yl}-3-methyl-1H-pyrazol-4-yl)methyl]azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.91 Å R-free 0.241 |
| 4XG9 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X9G 1-[(1-{2-[(3-chloro-1,2-dimethyl-1H-indol-5-yl)amino]pyrimidin-4-yl}-3-methyl-1H-pyrazol-4-yl)methyl]azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.91 Å R-free 0.241 |
| 4YJO THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222 Deposited 2015-03-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
Fragment：UNP residues 355-635
|
Not recorded | 4DF 5-chloro-N~2~-(1,1-dioxido-2,3-dihydro-1,2-benzothiazol-6-yl)-N~4~-ethyl-N~4~-(1H-indazol-4-yl)pyrimidine-2,4-diamine × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.8, 5mM TCEP
|
Resolution 1.60 Å R-free 0.230 |
| 4YJP THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223 Deposited 2015-03-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
Fragment：UNP residues 355-635
|
Not recorded | 4DL 2-[{2-[(1,1-dioxido-2,3-dihydro-1,2-benzothiazol-6-yl)amino]pyrimidin-4-yl}(1H-indazol-4-yl)amino]ethanol × 1 DMS DIMETHYL SULFOXIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.8, 5mM TCEP
|
Resolution 1.83 Å R-free 0.258 |
| 4YJQ SYK kinase domain in complex with inhibitor GTC000224 Deposited 2015-03-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
Fragment：UNP residues 355-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 4DK 3-[1H-indazol-4-yl(2-{[3-(4-methyl-1,3-oxazol-5-yl)phenyl]amino}pyrimidin-4-yl)amino]propan-1-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.0, 5mM TCEP
|
Resolution 1.34 Å R-free 0.183 |
| 4YJR SYK kinase domain in complex with inhibitor GTC000225 Deposited 2015-03-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
Fragment：UNP residues 355-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 4DJ 3-(1H-indazol-4-yl{2-[(1-methyl-1H-indazol-5-yl)amino]pyrimidin-4-yl}amino)propan-1-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.0, 5mM TCEP
|
Resolution 1.32 Å R-free 0.180 |
| 4YJS THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226 Deposited 2015-03-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
Fragment：UNP residues 355-635
|
Not recorded | 4DN 3-[{2-[(1,1-dioxido-2,3-dihydro-1,2-benzothiazol-6-yl)amino]pyrimidin-4-yl}(1H-indazol-4-yl)amino]propan-1-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；32.5% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.8, 5mM DTT
|
Resolution 2.22 Å R-free 0.226 |
| 4YJT THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233 Deposited 2015-03-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
Fragment：UNP residues 355-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | GOL GLYCEROL × 1 4DQ N~2~-(1,1-dioxido-2,3-dihydro-1,2-benzothiazol-6-yl)-N~4~-ethyl-5-fluoro-N~4~-(1H-indazol-4-yl)pyrimidine-2,4-diamine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.0, 5mM TCEP
|
Resolution 1.52 Å R-free 0.208 |
| 4YJU THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249 Deposited 2015-03-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
Fragment：UNP residues 355-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 4DO N~2~-(1,1-dioxido-2,3-dihydro-1,2-benzothiazol-6-yl)-5-fluoro-N~4~-(1H-indazol-4-yl)-N~4~-methylpyrimidine-2,4-diamine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.8, 5mM TCEP
|
Resolution 1.67 Å R-free 0.201 |
| 4YJV THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250 Deposited 2015-03-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
Fragment：UNP residues 355-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 4DT 3-[6-({4-[ethyl(1H-indazol-4-yl)amino]-5-fluoropyrimidin-2-yl}amino)-2,4-dihydro-1H-indazol-1-yl]propan-1-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.0, 5mM TCEP
|
Resolution 1.65 Å R-free 0.222 |
| 5C26 Crystal structure of SYK in complex with compound 1 Deposited 2015-06-15 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
343–635（293 aa）
Fragment：UNP residues 343-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 50H 3-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}benzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.5；295 K；1.75 M ammonium sulfate, 0.1 M sodium citrate, 0.1 M sodium acetate pH 5.5
|
Resolution 1.95 Å R-free 0.215 |
| 5C27 Crystal structure of SYK in complex with compound 2 Deposited 2015-06-15 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
343–635（293 aa）
Fragment：UNP residues 343-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 50J 3-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-N-[4-(methylcarbamoyl)phenyl]benzamide × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 5.5；298 K；1.75 M ammonium sulfate, 0.1 M sodium citrate, 0.1 M sodium acetate pH 5.5
|
Resolution 2.15 Å R-free 0.225 |
| 5CXH SYK catalytic domain complexed with a potent orally bioavailable thiazole inhibitor Deposited 2015-07-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：Protein kinase domain residues 356-635
|
Mutation：K467T | 55M (4R)-4-[(1R)-1-{[6-(3,4-dimethoxyphenyl)[1,3]thiazolo[5,4-c]pyridin-4-yl]oxy}ethyl]pyrrolidin-2-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.3；277 K；20% PEG3350, 0.2M potassium fluoride, no buffer pH 7.3
|
Resolution 1.90 Å R-free 0.205 |
| 5CXZ SYK catalytic domain complexed with naphthyridine inhibitor Deposited 2015-07-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 356-635
|
Mutation：K467T | GOL GLYCEROL × 1 CL CHLORIDE ION × 1 55U N-{7-[4-(dimethylamino)phenyl]-1,6-naphthyridin-5-yl}propane-1,3-diamine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 15%, cesium chloride 0.15M
|
Resolution 1.70 Å R-free 0.208 |
| 5CY3 SYK catalytic domain complexed with a potent and orally bioavailable benzisothiazole inhibitor Deposited 2015-07-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：residues 356-635
|
Mutation：K467T | 55Y (5R)-5-[(1R)-1-{[6-(1-methyl-1H-pyrazol-4-yl)-2,1-benzothiazol-4-yl]oxy}ethyl]-1,3-oxazolidin-2-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.1；293 K；PEG 3350 20%, ammonium acetate 0.2M
|
Resolution 1.76 Å R-free 0.195 |
| 5GHV Crystal structure of an inhibitor-bound Syk Deposited 2016-06-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
|
Not recorded | X5G 1-({1-[2-({3,5-dimethyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]-4-methyl-1H-pyrrol-3-yl}methyl)azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(V/V) PEG3350, 100 MM TRIS-HCL
|
Resolution 2.80 Å R-free 0.227 |
| 5GHV Crystal structure of an inhibitor-bound Syk Deposited 2016-06-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
|
Not recorded | X5G 1-({1-[2-({3,5-dimethyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]-4-methyl-1H-pyrrol-3-yl}methyl)azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(V/V) PEG3350, 100 MM TRIS-HCL
|
Resolution 2.80 Å R-free 0.227 |
| 5LMA HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR Deposited 2016-07-29 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
360–635（276 aa）
Fragment：UNP residues 360-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 6ZG ~{N}'-[7-(4-methylphenyl)pyrido[3,4-b]pyrazin-5-yl]butane-1,4-diamine × 1 GOL GLYCEROL × 2 DMS DIMETHYL SULFOXIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG3350, Sodium formate.
|
Resolution 1.43 Å R-free 0.183 |
| 5T68 Crystal structure of Syk catalytic domain in complex with a furo[3,2-d]pyrimidine Deposited 2016-09-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 356-635
Chain B
356–635（280 aa）
Fragment：UNP residues 356-635
|
Not recorded | 77V N~4~-cyclopropyl-N~2~-(3-methyl-1H-indazol-6-yl)furo[3,2-d]pyrimidine-2,4-diamine × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；14-18% PEG3350, 100 mM Tris pH 8.5 using a seed stock that was grown in PEG 3350 13-20% and 100 mM Tris pH 8.5
|
Resolution 2.93 Å R-free 0.281 |
| 5TIU Crystal structure of SYK kinase domain with inhibitor Deposited 2016-10-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 356-635
|
Not recorded | 7CU 5-{[(2S)-2-aminopropyl]amino}-3-(1H-indol-2-yl)pyrazine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277.15 K；16% PEG3350, 0.1M Tris pH 7.1-7.4
|
Resolution 1.49 Å R-free 0.203 |
| 5TR6 Discovery of TAK-659, an Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK) Deposited 2016-10-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 356-635
|
Not recorded | 7KG 6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one × 1 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.1；293 K；0.7M Potassium Na Tartrate, 0.06M MES_Na, 0.04M MES
|
Resolution 1.93 Å R-free 0.217 |
| 5TT7 Discovery of TAK-659, an Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK) Deposited 2016-11-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 356-635
|
Not recorded | 7KF 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.7；293 K；1.2M Potassium Na Tartrate, 0.1M Tris pH 8.7
|
Resolution 1.77 Å R-free 0.234 |
| 5Y5T Crystal structures of spleen tyrosine kinase in complex with a novel inhibitor Deposited 2017-08-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 356-635
|
Not recorded | 8OR 2-[[(1S,2S)-2-azanylcyclohexyl]amino]-4-[(4-methylsulfonylphenyl)amino]-6H-pyrido[4,3-d]pyrimidin-5-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；10-20% PEG 3350, 100mM Tris-HCl, pH 8.5
|
Resolution 1.80 Å R-free 0.234 |
| 5Y5U Crystal structures of spleen tyrosine kinase in complex with a novel inhibitor Deposited 2017-08-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 356-635
|
Not recorded | 8OU 4-[(1-methylindazol-5-yl)amino]-2-(4-oxidanylpiperidin-1-yl)-8H-pyrido[4,3-d]pyrimidin-5-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；10-20% PEG 3350, 100mM Tris-HCl, pH 8.5
|
Resolution 2.14 Å R-free 0.260 |
| 5Y5U Crystal structures of spleen tyrosine kinase in complex with a novel inhibitor Deposited 2017-08-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
356–635（280 aa）
Fragment：UNP residues 356-635
|
Not recorded | 8OU 4-[(1-methylindazol-5-yl)amino]-2-(4-oxidanylpiperidin-1-yl)-8H-pyrido[4,3-d]pyrimidin-5-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；10-20% PEG 3350, 100mM Tris-HCl, pH 8.5
|
Resolution 2.14 Å R-free 0.260 |
| 6HM6 CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A 2-(PYRIDINYLOXYMETHYL)PYRIDINE INHIBITOR Deposited 2018-09-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
337–612（276 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | GDK 2-(4-methylphenyl)-3-(pyridin-2-ylmethoxy)pyridine × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG 1500, HEPES, glycerol, tacsimate.
|
Resolution 2.10 Å R-free 0.290 |
| 6HM7 CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A 2-(PHENOXYMETHYL)PYRIDINE INHIBITOR Deposited 2018-09-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
337–612（276 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | GDH 7-[2-methoxy-6-[(4-methylpyridin-2-yl)methoxy]phenyl]-2,3,4,5-tetrahydro-1~{H}-3-benzazepine × 1 BR BROMIDE ION × 3 GOL GLYCEROL × 1 DMS DIMETHYL SULFOXIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；PEG 3350, bistrispropane, sodium bromide
|
Resolution 1.64 Å R-free 0.210 |
| 6SSB syk in complex with compound 30 Deposited 2019-09-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | LUE ~{N}-[4-[5-[(dimethylamino)methyl]-1-methyl-pyrazol-3-yl]pyrimidin-2-yl]-3-methyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)imidazo[1,5-a]pyridin-7-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.4；293 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 2.08 Å R-free 0.225 |
| 6VOV Crystal structure of Syk in complex with GS-9876 Deposited 2020-01-31 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
363–635（273 aa）
Fragment：UNP Residues 363-635
|
Not recorded | R6D 6-(6-aminopyrazin-2-yl)-N-{4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；20% PEG 3350, 100mM Tris pH 8.5
|
Resolution 1.95 Å R-free 0.268 |
| 6VOV Crystal structure of Syk in complex with GS-9876 Deposited 2020-01-31 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
363–635（273 aa）
Fragment：UNP Residues 363-635
|
Not recorded | R6D 6-(6-aminopyrazin-2-yl)-N-{4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；20% PEG 3350, 100mM Tris pH 8.5
|
Resolution 1.95 Å R-free 0.268 |
| 6ZC0 SYK Kinase domain in complex with azabenzimidazole inhibitor 2b Deposited 2020-06-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | QDZ ~{N},~{N}-dimethyl-1-[1-[2-(1-methylindol-4-yl)-3~{H}-imidazo[4,5-b]pyridin-7-yl]pyrazol-4-yl]methanamine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 1.97 Å R-free 0.229 |
| 6ZCP SYK Kinase domain in complex with azabenzimidazole inhibitor 2b Deposited 2020-06-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | QFK 7-[[4-[4-[(dimethylamino)methyl]pyrazol-1-yl]pyrimidin-2-yl]amino]-~{N},3-dimethyl-imidazo[1,5-a]pyridine-1-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；278 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 2.20 Å R-free 0.234 |
| 6ZCQ SYK Kinase domain in complex with diamine inhibitor 5 Deposited 2020-06-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | QFB 7-[[4-[4-[[(3~{R},4~{R})-3-azanyloxan-4-yl]amino]pyrazol-1-yl]pyrimidin-2-yl]amino]-~{N},3-dimethyl-imidazo[1,5-a]pyridine-1-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；278 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 2.32 Å R-free 0.244 |
| 6ZCR SYK Kinase domain in complex with azabenzimidazole inhibitor 7 Deposited 2020-06-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | 5JG 6-chloro-2-(2-fluoro-4,5-dimethoxyphenyl)-N-(piperidin-4-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；278 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 1.73 Å R-free 0.218 |
| 6ZCS SYK Kinase domain in complex with azabenzimidazole inhibitor 3 Deposited 2020-06-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | QFE (3~{R},4~{R})-~{N}4-[1-[2-(1-methylindol-4-yl)-3~{H}-imidazo[4,5-b]pyridin-7-yl]pyrazol-4-yl]oxane-3,4-diamine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；278 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 1.47 Å R-free 0.208 |
| 6ZCU syk in complex with 57262_SYKB-AZ13344324-2 Deposited 2020-06-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | 5JG 6-chloro-2-(2-fluoro-4,5-dimethoxyphenyl)-N-(piperidin-4-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 1.73 Å R-free 0.218 |
| 6ZCX SYK Kinase domain in complex with azabenzimidazole inhibitor 18 Deposited 2020-06-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | QFQ ~{N},1-dimethyl-5-[[4-[3-methyl-4-[[(3~{R})-piperidin-3-yl]amino]pyrazol-1-yl]pyrimidin-2-yl]amino]indazole-3-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；278 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 1.66 Å R-free 0.229 |
| 6ZCY SYK Kinase domain in complex with diamine inhibitor 16 Deposited 2020-06-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | QF8 ~{N},1-dimethyl-5-[[4-[3-methyl-4-[[(3~{R})-pyrrolidin-3-yl]amino]pyrazol-1-yl]pyrimidin-2-yl]amino]indazole-3-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；278 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 1.81 Å R-free 0.223 |
| 7Q5T The tandem SH2 domains of SYK with a bound FCER1G diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain AAA
6–269（264 aa）
|
Not recorded | PO4 PHOSPHATE ION × 2 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.255 |
| 7Q5T The tandem SH2 domains of SYK with a bound FCER1G diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain BBB
6–269（264 aa）
|
Not recorded | PO4 PHOSPHATE ION × 2 PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.255 |
| 7Q5T The tandem SH2 domains of SYK with a bound FCER1G diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain CCC
6–269（264 aa）
|
Not recorded | PO4 PHOSPHATE ION × 2 EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.255 |
| 7Q5T The tandem SH2 domains of SYK with a bound FCER1G diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain DDD
6–269（264 aa）
|
Not recorded | PO4 PHOSPHATE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.255 |
| 7Q5T The tandem SH2 domains of SYK with a bound FCER1G diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain EEE
6–269（264 aa）
|
Not recorded | PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.255 |
| 7Q5T The tandem SH2 domains of SYK with a bound FCER1G diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain FFF
6–269（264 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.255 |
| 7Q5U The tandem SH2 domains of SYK with a bound CD3G diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain AAA
6–269（264 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 2 PEG DI(HYDROXYETHYL)ETHER × 1 P4G 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；100 mM MMT buffer, 30% PEG 1000
|
Resolution 2.40 Å R-free 0.259 |
| 7Q5U The tandem SH2 domains of SYK with a bound CD3G diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain BBB
6–269（264 aa）
|
Not recorded | PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；100 mM MMT buffer, 30% PEG 1000
|
Resolution 2.40 Å R-free 0.259 |
| 7Q5U The tandem SH2 domains of SYK with a bound CD3G diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain CCC
6–269（264 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；100 mM MMT buffer, 30% PEG 1000
|
Resolution 2.40 Å R-free 0.259 |
| 7Q5U The tandem SH2 domains of SYK with a bound CD3G diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain DDD
6–269（264 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；100 mM MMT buffer, 30% PEG 1000
|
Resolution 2.40 Å R-free 0.259 |
| 7Q5U The tandem SH2 domains of SYK with a bound CD3G diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain EEE
6–269（264 aa）
|
Not recorded | PEG DI(HYDROXYETHYL)ETHER × 1 P4G 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；100 mM MMT buffer, 30% PEG 1000
|
Resolution 2.40 Å R-free 0.259 |
| 7Q5U The tandem SH2 domains of SYK with a bound CD3G diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain FFF
6–269（264 aa）
|
Not recorded | PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；100 mM MMT buffer, 30% PEG 1000
|
Resolution 2.40 Å R-free 0.259 |
| 7Q5W The tandem SH2 domains of SYK with a bound TYROBP diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain AAA
6–269（264 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.266 |
| 7Q5W The tandem SH2 domains of SYK with a bound TYROBP diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain BBB
6–269（264 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.266 |
| 7Q5W The tandem SH2 domains of SYK with a bound TYROBP diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain CCC
6–269（264 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.266 |
| 7Q5W The tandem SH2 domains of SYK with a bound TYROBP diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain DDD
6–269（264 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.266 |
| 7Q5W The tandem SH2 domains of SYK with a bound TYROBP diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain EEE
6–269（264 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 P4G 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.266 |
| 7Q5W The tandem SH2 domains of SYK with a bound TYROBP diphospho-ITAM peptide Deposited 2021-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain FFF
6–269（264 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.266 |
| 7Q63 The tandem SH2 domains of SYK Deposited 2021-11-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain AAA
6–269（264 aa）
|
Not recorded | PEG DI(HYDROXYETHYL)ETHER × 1 SCN THIOCYANATE ION × 3 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；200 mM, potassium thiocyanate, 12.5% glycerol, 23% PEG3350
|
Resolution 1.90 Å R-free 0.264 |
| 7Q63 The tandem SH2 domains of SYK Deposited 2021-11-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain BBB
6–269（264 aa）
|
Not recorded | SCN THIOCYANATE ION × 4 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；200 mM, potassium thiocyanate, 12.5% glycerol, 23% PEG3350
|
Resolution 1.90 Å R-free 0.264 |
| 7Q63 The tandem SH2 domains of SYK Deposited 2021-11-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain CCC
6–269（264 aa）
|
Not recorded | SCN THIOCYANATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；200 mM, potassium thiocyanate, 12.5% glycerol, 23% PEG3350
|
Resolution 1.90 Å R-free 0.264 |
| 7SA7 Crystal structure of the apo SH2 domains of Syk Deposited 2021-09-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
6–269（264 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Protein- 35mg/mL in 10mM HEPES pH 7.0, 50mM NaCl, 5% glycerol and 1mM TCEP
Crystal conditions-0.2M sodium nitrate and 10% w/v PEG 3350
Cryoprotectant-0.2M sodium nitrate, 20% PEG 3350, and 20% glycerol
|
Resolution 3.20 Å R-free 0.304 |
| 7SA7 Crystal structure of the apo SH2 domains of Syk Deposited 2021-09-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
6–269（264 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Protein- 35mg/mL in 10mM HEPES pH 7.0, 50mM NaCl, 5% glycerol and 1mM TCEP
Crystal conditions-0.2M sodium nitrate and 10% w/v PEG 3350
Cryoprotectant-0.2M sodium nitrate, 20% PEG 3350, and 20% glycerol
|
Resolution 3.20 Å R-free 0.304 |
| 7SA7 Crystal structure of the apo SH2 domains of Syk Deposited 2021-09-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
6–269（264 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Protein- 35mg/mL in 10mM HEPES pH 7.0, 50mM NaCl, 5% glycerol and 1mM TCEP
Crystal conditions-0.2M sodium nitrate and 10% w/v PEG 3350
Cryoprotectant-0.2M sodium nitrate, 20% PEG 3350, and 20% glycerol
|
Resolution 3.20 Å R-free 0.304 |
| 7SA7 Crystal structure of the apo SH2 domains of Syk Deposited 2021-09-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain D
6–269（264 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Protein- 35mg/mL in 10mM HEPES pH 7.0, 50mM NaCl, 5% glycerol and 1mM TCEP
Crystal conditions-0.2M sodium nitrate and 10% w/v PEG 3350
Cryoprotectant-0.2M sodium nitrate, 20% PEG 3350, and 20% glycerol
|
Resolution 3.20 Å R-free 0.304 |
| 7SA7 Crystal structure of the apo SH2 domains of Syk Deposited 2021-09-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 5 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain E
6–269（264 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Protein- 35mg/mL in 10mM HEPES pH 7.0, 50mM NaCl, 5% glycerol and 1mM TCEP
Crystal conditions-0.2M sodium nitrate and 10% w/v PEG 3350
Cryoprotectant-0.2M sodium nitrate, 20% PEG 3350, and 20% glycerol
|
Resolution 3.20 Å R-free 0.304 |
| 7SA7 Crystal structure of the apo SH2 domains of Syk Deposited 2021-09-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 6 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain F
6–269（264 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Protein- 35mg/mL in 10mM HEPES pH 7.0, 50mM NaCl, 5% glycerol and 1mM TCEP
Crystal conditions-0.2M sodium nitrate and 10% w/v PEG 3350
Cryoprotectant-0.2M sodium nitrate, 20% PEG 3350, and 20% glycerol
|
Resolution 3.20 Å R-free 0.304 |
| 8BI2 Syk kinase domain in complex with macrocyclic inhibitor 20a Deposited 2022-11-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | QR7 10,13,23-trimethyl-16-oxa-2,4,8,9,13,19,23,30-octazapentacyclo[19.5.2.1^{3,7}.1^{8,11}.0^{24,28}]triaconta-1(27),3,5,7(30),9,11(29),21,24(28),25-nonaen-20-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.4；274 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 1.51 Å R-free 0.235 |
| 8RRQ Crystal structure of human SYK in complex with compound 24 Deposited 2024-01-23 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | A1H2W N-[(1S,2R)-2-azanylcyclohexyl]-5-[2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl]-2-methyl-pyrazole-3-carboxamide × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；277 K；20% PEG 3350, 0.1 M bis tris propane pH 6.5, 0.2 M Na formate
|
Resolution 1.60 Å R-free 0.211 |
| 8RRZ Crystal structure of SYK kinase in complex with compound 1 Deposited 2024-01-24 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | A1H2Y N-[(2S)-1-(azetidin-1-yl)propan-2-yl]-3-{2-[(3,5-dimethoxyphenyl)amino]pyrimidin-4-yl}-1-methyl-1H-pyrazole-5-carboxamide × 1 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；277 K；20% PEG 3350, 0.1 M bis tris propane pH 6.5, 0.2 M Na formate
|
Resolution 1.75 Å R-free 0.214 |
| 8WYW Crystal structure of spleen tyrosine kinase (SYK) in complex with SKI-O-592 (free form of SKI-O-703, cevidoplenib) Deposited 2023-10-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 356-635
Chain B
356–635（280 aa）
Fragment：UNP residues 356-635
|
Not recorded | XFB SKI-O-592 × 2 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；100mM Sodium-HEPES 7.0, 15%(v/v)PEG 4000
|
Resolution 1.90 Å R-free 0.242 |
| 8X5K The Crystal Structure of SYK from Biortus. Deposited 2023-11-17 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
|
Not recorded | 3YT 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-{[3-(2H-1,2,3-triazol-2-yl)phenyl]amino}pyrimidine-5-carboxamide × 1 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M Li2SO4, 0.1M Bis-Tris pH6.5, 25% PEG 3350
|
Resolution 1.80 Å R-free 0.244 |
| 8XQ0 Crystal structure of spleen tyrosine kinase(SYK)in complex with SKI-G-1653 Deposited 2024-01-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
Chain B
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
Chain C
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
Chain D
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
|
Not recorded | A1LV4 cyclopropyl-[5-[[4-[4-[[(3~{S},4~{S})-3-methoxy-4-oxidanyl-pyrrolidin-1-yl]methyl]-3-methyl-pyrazol-1-yl]pyrimidin-2-yl]amino]-1-methyl-indol-3-yl]methanone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1M HEPES pH 7.0, 10% PEG 6000
|
Resolution 1.95 Å R-free 0.265 |
| 8XQ1 Crystal structure of spleen tyrosine kinase(SYK) in complex with SKI-G-1673 Deposited 2024-01-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
Chain B
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
|
Not recorded | A1LV6 cyclopropyl-[5-[[4-[4-[[(3~{R},4~{S})-3-methoxy-4-oxidanyl-pyrrolidin-1-yl]methyl]-3-methyl-pyrazol-1-yl]pyrimidin-2-yl]amino]-1-methyl-pyrrolo[2,3-b]pyridin-3-yl]methanone × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1M Bis-Tris pH 6.5, 20% PEG 1500
|
Resolution 1.50 Å R-free 0.209 |
| 8XQ2 Crystal structure of spleen tyrosine kinase(SYK)in complex with SKI-G-1693 Deposited 2024-01-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
Chain B
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
|
Not recorded | GOL GLYCEROL × 1 A1LV7 cyclopropyl-[1-(2-fluoranylethyl)-5-[[4-[4-[[(3~{R},4~{S})-3-methoxy-4-oxidanyl-pyrrolidin-1-yl]methyl]-3-methyl-pyrazol-1-yl]pyrimidin-2-yl]amino]indol-3-yl]methanone × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1M tris-HCl pH 8.5, 10% PEG 3350
|
Resolution 1.80 Å R-free 0.238 |
92 other PDB entries and 133 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | KSYK_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A； PDBConstruct 2–277； UniProt 360–635 Author chain B； PDBConstruct 2–277； UniProt 360–635 |
